EGFR blockade in GBM brain tumor stem cells synergizes with JAK2/STAT3 pathway inhibition to abrogate compensatory mechanisms in vitro and in vivo
Open Access
- 1 January 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 2 (1) , vdaa020
Abstract
The EGFR pathway is frequently mutated in glioblastoma (GBM). However, to date, EGFR therapies have not demonstrated efficacy in clinical trials. Poor brain penetration of conventional inhibitors, lack of patient stratification for EGFR status, and mechanisms of resistance are likely responsible for the failure of EGFR-targeted therapy. We aimed to address these elements in a large panel of molecularly diverse patient-derived GBM brain tumor stem cells (BTSCs). In vitro growth inhibition and on-target efficacy of afatinib, pacritinib, or a combination were assessed by cell viability, neurosphere formation, cytotoxicity, limiting dilution assays, and western blotting. In vivo efficacy was assessed with mass spectrometry, immunohistochemistry, magnetic resonance imaging, and intracranial xenograft models. We show that afatinib and pacritinib decreased BTSC growth and sphere-forming capacity in vitro. Combinations of the 2 drugs were synergistic and abrogated the activation of STAT3 signaling observed upon EGFR inhibition in vitro and in vivo. We further demonstrate that the brain-penetrant EGFR inhibitor, afatinib, improved survival in EGFRvIII mt orthotopic xenograft models. However, upregulation of the oncogenic STAT3 signaling pathway was observed following afatinib treatment. Combined inhibition with 2 clinically relevant drugs, afatinib and pacritinib, synergistically decreased BTSC viability and abrogated this compensatory mechanism of resistance to EGFR inhibition. A significant decrease in tumor burden in vivo was observed with the combinatorial treatment. These data demonstrate that brain-penetrant combinatorial therapies targeting the EGFR and STAT3 signaling pathways hold therapeutic promise for GBM.Keywords
Funding Information
- Canadian Institutes of Health Research
- Cell Therapeutics Inc Biopharma
- Alberta Cancer Foundation
- SU2C Canada Cancer Stem Cell Dream Team Research (SU2C-AACR-DT-19-15)
This publication has 48 references indexed in Scilit:
- Inhibition of STAT3 by Niclosamide Synergizes with Erlotinib against Head and Neck CancerPLOS ONE, 2013
- Understanding resistance to EGFR inhibitors—impact on future treatment strategiesNature Reviews Clinical Oncology, 2010
- The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradationProceedings of the National Academy of Sciences, 2010
- A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapyNeuro-Oncology, 2009
- STAT3 Is Required for Proliferation and Maintenance of Multipotency in Glioblastoma Stem CellsStem Cells, 2009
- Proliferation of Human Glioblastoma Stem Cells Occurs Independently of Exogenous MitogensStem Cells, 2009
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- Molecular Determinants of the Response of Glioblastomas to EGFR Kinase InhibitorsNew England Journal of Medicine, 2005
- EGFRMutations and Sensitivity to GefitinibNew England Journal of Medicine, 2004
- Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cellsOncogene, 2002